Pacira BioSciences, Inc. PCRX Accounts Receivable
Accounts Receivable at other companies
Other financials
Where this comes from
Reported directly by Pacira BioSciences, Inc. in its filing.
Tagged under the XBRL concept us-gaap:AccountsReceivableNetCurrent.
The official record: Pacira BioSciences, Inc.’s 10-Q, filed April 30, 2026, on SEC EDGAR. View the filing →
Ask your AI about Pacira BioSciences, Inc.'s accounts receivable.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Pacira BioSciences, Inc.'s accounts receivable?
- Pacira BioSciences, Inc. (PCRX) reported accounts receivable of $125.64M in Q1 2026.
- How has Pacira BioSciences, Inc.'s accounts receivable changed year-over-year?
- Pacira BioSciences, Inc.'s accounts receivable increased by 19.9% year-over-year, from $104.75M to $125.64M.
- What is the long-term trend for Pacira BioSciences, Inc.'s accounts receivable?
- Over 5 years (2020 to 2025), Pacira BioSciences, Inc.'s accounts receivable has grown at a 18.5% compound annual growth rate (CAGR), from $53.05M to $124.07M.
- What does accounts receivable mean?
- Amounts owed by customers for goods delivered or services performed, net of allowances for doubtful accounts. A key working capital component.